Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. (Q54404882)

29 May 2018

title

Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. (English)

1 reference

29 May 2018

author name string

Jun Gu

1

1 reference

29 May 2018

Xu Liu

2

1 reference

29 May 2018

Quan-Xing Wang

3

1 reference

29 May 2018

Meng Guo

4

1 reference

29 May 2018

Fang Liu

5

1 reference

29 May 2018

Zhi-Ping Song

6

1 reference

29 May 2018

Da-Dong Zhang

7

1 reference

29 May 2018

publication date

4 October 2013

1 reference

29 May 2018

Journal of Molecular and Cellular Cardiology

published in

1 reference

29 May 2018

volume

65

1 reference

29 May 2018

page(s)

1-8

1 reference

29 May 2018

Atrial fibrillation pathophysiology: implications for management.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Angiotensin II induces complex fractionated electrogram in a cultured atrial myocyte monolayer mediated by calcium and sodium-calcium exchanger.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Ionic mechanisms of electrical remodeling in human atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Effects of irbesartan on gene expression revealed by transcriptome analysis of left atrial tissue in a porcine model of acute rapid pacing in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Extracellular matrix of collagen modulates intracellular calcium handling and electrophysiological characteristics of HL-1 cardiomyocytes with activation of angiotensin II type 1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Recent advances in the molecular pathophysiology of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Dynamic remodeling of intracellular Ca²⁺ signaling during atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor β1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.09.016

10.1016/J.YJMCC.2013.09.016

7 January 2021

Identifiers

DOI

1 reference

29 May 2018

PubMed ID

24100253

1 reference

29 May 2018